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DObjectives: To identify and understand residual patient, anatomic, and surgical obstacles in treating active
left-sided infective endocarditis (IE), we categorized the intraoperative pathologic entities in patients with
left-sided IE and correlated the pathology (noninvasive vs invasive) and organism with IE context (affected
valve, native vs prosthetic [PVE]) and surgical results.
Methods: From January 2002 to January 2011, 775 patients underwent surgery for active left-sided IE.
Registries were queried, and endocarditis-related pathology was based on the echocardiographic findings
and operative notes. Propensity adjustment and matching (55 pairs) were used for risk-adjusted outcome
comparisons between the invasive aortic and mitral cases.
Results: A total of 395 patients had isolated aortic (PVE 59%, invasive 68%), 238 isolated mitral (PVE 29%,
invasive 35%), and 142 combined aortic andmitral (PVE 44%, invasive 69%) IE. The 30-day survival was 92%
and was similar for native valve endocarditis and PVE in all 3 valve combinations. Invasive versus noninvasive
IE was associated with greater hospital mortality (11% vs 4.4%, P¼ .001). Patients with invasive IE had worse
intermediate-term survival than those with noninvasive IE for mitral (P¼ .001) and aortic plus mitral (P ¼ .02)
IE but not for isolated aortic IE. This difference persisted in the matched patients.
Conclusions:During the past decade, we have had low hospital mortality for surgically treated left-sided IE and
have neutralized the added risk of PVE. However, outcomes remain worse for mitral versus aortic valve IE, with
residual obstacles related to patient factors, inherent mitral valve anatomy in patients with invasive disease, and
lack of an alternative mitral valve prosthesis optimal for IE. (J Thorac Cardiovasc Surg 2014;148:981-8)Supplemental material is available online.
The objectives of surgery for infective endocarditis (IE) are to
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The Journal of Thoracic and Cafunctional valves. Despite the reduction of operative
mortality and risk of subsequent prosthetic valve endocarditis
(PVE) by a strategy that includes early radical surgery, the
risks remain greater than those of operations for any other
valve disease.1-6 These risks are related not only to the
surgical challenges of treating IE but also to patient
comorbidities and the local and systemic consequences of
the IE: Local effects manifested by pathology stage related
to the involved valve, and systemic effects by embolic
events and dissemination and toxicity of the infection, both
organism and time related. Traditionally, aortic and mitral
valve endocarditis results are presented together or
separately, and the outcomes have been related to
general disease factors such as PVE, the presence of
abscesses, or an aggressive organism. This has prevented
the identification of both commonalities and contrasts of
pathologic features and outcomes across the spectrum of
left-sided IE.
Thus, the primary objectives of the present study were to
identify and understand the residual patient, anatomic, and
surgical obstacles to reducing the risk of surgical treatment
of active left-sided IE. To accomplish this, we categorized
the spectrum of intraoperative pathologic features in
patients with active left-sided IE, correlated the pathology
stage (noninvasive vs invasive IE) and organism with the
IE context (affected valve, native valve endocarditisrdiovascular Surgery c Volume 148, Number 3 981
Abbreviations and Acronyms
IE ¼ infective endocarditis
NVE ¼ native valve endocarditis
PVE ¼ prosthetic valve endocarditis
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D[NVE] vs PVE) and surgical results, and compared the
outcomes after accounting for patient morbidities.
METHODS
Patients
From January 1, 2002, to January 1, 2011, 963 left-sided IE cases were
identified from the existing infectious disease and cardiac surgery registries,
the medical records were reviewed, and the patients were classified using
modifiedDuke criteria.7 Only cases meeting criteria for active aortic or mitral
IE were included in the study1,8; healed and remote endocarditis (188 cases,
20% of left-sided IE) were excluded, leaving a study population of 775 cases.
Of these, 395 patients (51%) had isolated aortic valve IE, 238 (31%) isolated
mitral valve IE, and 142 (18%) combined aortic and mitral valve IE. Patient
characteristics, operative procedure details, and hospital outcomes were
extracted from a prospective registry of all cardiac operations, and the micro-
biologic laboratory results and infectious disease serologywere retrieved from
the infectious disease registry. TheClevelandClinic institutional review board
approved the use of data extracted from all registries and a de novo review of
the medical records for use in research, with patient consent waived.
IE Characteristics
The etiology of IE was determined by review of the microbiologic
laboratory results and infectious disease serology. The surgical pathologic
type was coded and stored in a Research Electronic Data Capture database,
as previously described.8 Coding was determined from reviews of patient
records, operative reports, and pre- and intraoperative transesophageal echo-
cardiograms. IEwas defined as noninvasive if itwas confined to the cusps and
leaflets and invasive if the infectious process extended beyond the cusp or
leaflets into the annulus and surrounding structures. All pathologic findings
were coded by the same surgeon (S.T.H.) retrospectively until 2008 and
prospectively from January 2009 onward (in close collaborationwithG.B.P.).
IE Management
AtClevelandClinic, patients presentingwith IE are treatedby amultispeci-
alty team. Surgery is advocated as soon as an indication has been established;
we do notwait for heart failure to develop. However,many patients are already
in heart failure when referred. All patients undergo brain imaging preopera-
tively to exclude hemorrhagic stroke. Having effective antibiotics on board
at surgery is important, because we have seen persistent IE when this was
not the case. When a patient is stable and without an elevated risk of embolic
events, waiting for cultures and the sensitivity patternmay be justified. At sur-
gery, radical debridementof all infected tissuesand foreignmaterial is followed
by generous irrigation. Local antiseptics and antibiotics are used sparingly.
Allografts are preferred for aortic root reconstruction in patients with
annulus destruction and invasive disease. When the annulus can be
preserved, the choice of valve will not differ from that for other patients
with valve disease. Mitral valve repair is preferred, and replacements are
performed with chordal sparing when possible; autologous pericardium
is the preferred material when needed for additional reconstructions.1
Outcomes
Postoperative complications were defined according to The Society of
Thoracic Surgeons Adult Cardiac Surgery database (available at: http://
riskcalc.sts.org/STSWebRiskCalc273/About%20the%20STS%20Risk%
20Calculator%20v2.73.pdf).982 The Journal of Thoracic and Cardiovascular SurgFollow-up of all patients who have undergone a heart valve operation is
performed at 2 and 5 years and at 5-year intervals thereafter. This active
follow-up protocol was supplemented with Social Security Death Master
File information,9,10 with a closing date of April 27, 2011, 6 months
after the query on October 27, 2011. A total of 2465 patient-years of
follow-up data were available for analysis. Among the survivors, the
median follow-up was 3.5 years, with 25% followed up>6 years and
10%>7.5 years.
Data Analysis
Continuous variables are summarized as the mean standard deviation
or as the 15th, 50th (median), and 85th percentiles when the distribution
was skewed. Comparisons were made using the Wilcoxon rank-sum test.
Categorical data are summarized using frequencies and percentages.
Comparisons were made using the chi-square test or Fisher’s exact test
when the frequency was<5. All analyses were performed using SAS
statistical software, version 9.2 (SAS Institute, Inc, Cary, NC). Uncertainty
is expressed by 68% confidence limits equivalent to 1 standard error. In
all analyses, repaired native valves were included in the NVE group.
Risk factors for mortality. Survival was studied overall, by
affected valve, by NVE versus PVE, and by noninvasive versus invasive
disease, overall and, again, by affected valve. Nonparametric survival
estimates were obtained using the Kaplan-Meier method, and a parametric
method was used to resolve the number of phases of an instantaneous risk
of death (hazard function) and to estimate its shaping parameters.11
Thereafter, multivariable analyses were performed in the hazard function
domain. Initially, separate models were developed for the aortic and mitral
groups to uncover any possible interactions (varying effects of risk factors
for each valve). Next, variable selection (Appendix E1 lists the candidate
variables) was performed using bagging, with retention of variables with
at least a 50% chance of P < .05. For this, stepwise regression was
performed on 500 bootstrap data sets. Using the median rule, the variables
that appeared in 50% of the bootstrap models were retained in the final
model.12,13
Risk adjustment using propensity method. Risk adjustment
focused on invasive disease in the isolated aortic and isolated mitral valve
IE groups. Initially, a parsimonious model was developed to understand the
important differences between these 2 groups (Table E1). Multivariable
logistic regression analysis was used with preoperative (only) candidate
variables (Appendix E1). Variable selection used bagging and 1000
bootstrap samples, as described. Compared with invasive isolated aortic
valve IE, invasive isolated mitral valve IE was associated with NVE,
previous stroke, preoperative dialysis (acute or chronic), larger left atrial
size, and female sex (Table E2).
Thereafter, we augmented the parsimonious model with 17 other vari-
ables representing preoperative patient demographic data, symptoms, and
cardiac and noncardiac comorbidities that might be related to unrecorded
selection factors (semisaturated model). A propensity score was calculated
for each patient by solving the propensitymodel for the probability of being
in the mitral valve IE group (compared with aortic).14 Next, using only the
propensity score, patients with mitral IE were matched to patients with
aortic IE using a greedy matching strategy. Patients whose propensity
scores deviated >0.15 were considered unmatched. This yielded 55
well-matched patient pairs (Figure E1), 65% of the possible matches.RESULTS
Pathologic Characteristics
Of the 775 patients, 395 had aortic valve IE, 238 had
mitral valve IE, and 142 had combined aortic and mitral
valve IE (Table E3); 362 (47%) had PVE and 452 (58%)
had invasive IE (Table 1). Of the 395 patients with isolated
aortic valve IE, 232 (59%) had PVE and 270 (68%) hadery c September 2014
TABLE 1. Clinical characteristics of patients with left-sided infective endocarditis treated surgically
Characteristic
Infective endocarditis type Invasiveness




(n ¼ 452) P value
Demographic data
Age (y) 55  14 60  14 <.0001 55  14 59  15 <.0001
Female sex 139 (34) 91 (25) .012 111 (35) 121 (27) .02
Presentation
NYHA functional class III-IV 132 (32) 99 (27) .16 106 (33) 125 (28) .12
Emergency or salvage 22 (5.3) 20 (5.6) .9 14 (4.4) 27 (6.0) .4
Previous stroke 142 (34) 126 (35) .8 120 (37) 147 (33) .16
Previous MI 86 (21) 103/359 (29) .011 65/321 (20) 124/451 (27) .02
Complete heart block or pacer 18/408 (4.4) 45 (13) <.0001 12 (3.8) 51 (11) .0002
Acute or chronic renal disease requiring dialysis 70 (17) 37/359 (10) .008 38/321 (12) 69/451 (15) .17
Preoperative length of stay (d)* 1.8, 5.8, 12 1.9, 5.9, 13 .3 1.9, 6.2, 12 1.8, 5.4, 12 .05
Cardiac morbidity
Previous cardiac operation <.0001 <.0001
None 343 (83) 0 (0) 202 (63) 147 (33)
1 65 (16) 238 (66) 86 (27) 209 (46)
2 4 (0.96) 99 (28) 27 (8.4) 76 (17)
3 1 (0.24) 25 (7.0) 6 (1.8) 20 (4.5)
Aortic valve
Stenosis 41 (9.9) 14 (3.9) .001 15 (4.7) 40 (8.8) .02
Regurgitation grade 3þ/4þ 189 (46) 94 (26) <.0001 132 (41) 151 (33) .03
Mitral valve
Stenosis 23 (5.6) 9 (2.5) .03 16 (5.0) 16 (3.5) .3
Regurgitation grade 3þ/4þ 160 (39) 62 (17) <.0001 119 (37) 103 (23) <.0001
Noncardiac comorbidity
Hypertension 254 (62) 254 (70) .009 195 (61) 313 (69) .01
Pharmacologically treated DM 95/404 (24) 77/352 (22) .6 58/315 (18) 114/441 (26) .02
COPD 53 (13) 69 (19) .02 53/321 (17) 71/451 (16) .8
Peripheral arterial disease 57 (14) 35 (9.7) .10 39/321 (12) 53/451 (12) .9
Operative detailsy
AV repair 17 (4.1) 3 (0.83) — 16 (5.0) 4 (0.88) —
AV replacement
Mechanical 16 (3.9) 9 (2.5) — 15 (4.6) 10 (2.2) —
Xenograft 101 (24) 38 (11) — 90 (28) 49 (11) —
Allograft 111 (27) 246 (68) — 52 (16) 305 (67) —
MV repair 141 (34) 50 (14) — 94 (29) 97 (21) —
MV replacement
Mechanical 22 (5.3) 16 (4.4) — 23 (7.2) 15 (3.3) —
Xenograft 114 (28) 96 (27) — 99 (31) 111 (25) —
CPB time (min) 129  58 184  68 <.0001 120  50 179  69 <.0001
Aortic clamp time (min) 103  48 134  51 <.0001 91  39 135  52 <.0001
Data presented as mean  standard deviation or n (%), unless otherwise noted. NYHA, New York Heart Association; MI, myocardial infarction; DM, diabetes mellitus;
COPD, chronic obstructive pulmonary disease; AV, aortic valve; MV, mitral valve; CPB, cardiopulmonary bypass; IE, infective endocarditis; NVE, native valve endocarditis;
PVE, prosthetic valve endocarditis. *Data presented as 15th, 50th, 85th percentiles. yIncluded procedures on noninfected valves.
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Dinvasive IE. Of the 238 with isolated mitral valve IE, 68
(29%) had PVE (P<.0001 for the difference from aortic
valve IE) and 84 (35%) had invasive IE (P< .0001 for
difference from aortic valve IE). Of the 142 with double
valve IE, 11 (7%) had PVE of 1 valve and NVE of the other,
25 (18%) had PVE involving both valves, 77 (55%) had
NVE of both valves, and 3 (2%) had 1 repaired native valve;
97 patients (69%) had invasive disease.The Journal of Thoracic and CaFor patients with invasive disease, the stage of invasive-
ness was cellulitis in 305 (69%), abscess formation
in 344 (76%), an abscess cavity in 204 (45%), and a
pseudoaneurysm in 45 (9.9%; Table 2). Advanced
invasiveness was more common in thosewith isolated aortic
valve IE than in those with isolated mitral valve disease, just
as was full-circumference IE. PVE was most often
associated with invasive IE and NVE with noninvasive IE.rdiovascular Surgery c Volume 148, Number 3 983
TABLE 2. Valve pathology observed at surgery for left-sided infective endocarditis
Pathologic findings AV (n ¼ 395) MV (n ¼ 238)
AV þMV (n ¼ 142)
AV only MV only Both
Vegetations 329 (83) 224 (94) 11 (7.8) 15 (11) 111 (78)
Integrity abnormality of cusp or leaflet 123 (31) 119 (50) 21 (15) 36 (25) 36 (25)
Invasive disease* 270 (68) 84 (35) 54 (38) 7 (4.9) 37 (26)
Invasive disease stage*,y
Cellulitis 182 (67) 67 (80) 33 6 17
Abscess 220 (82) 41 (49) 60 1 16
Abscess cavity 126 (46) 20 (24) 38 3 14
Pseudoaneurysm 32 (12) 1 (1.2) 4 2 0
Invasive disease extent (annular circumference)
<1/3 74 (30) 38 (49) 20 5 6
1/3-1/2 96 (38) 33 (42) 29 16 8
Full circumference 80 (32) 7 (9.0) 16 0 2
Data presented as n (%). AV, Aortic valve; MV, mitral valve. *Percentage of invasive disease. yInvasive stage definitions as reported by Pettersson and colleagues.8
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coccus aureus, coagulase-negative S enterococcus, and
Streptococcus viridans (Table 3). Staphylococcus species
were most likely to be associated with invasive IE,
streptococcus least likely, with the degree of invasiveness
about equal for other organisms.
Hospital Outcomes
Hospital mortality was 8% overall, 7% for aortic valve
IE, 6% for mitral valve IE, and 14% for combined aortic
and mitral valve IE. Hospital mortality was higher (10%)
for those with PVE than for those with NVE (6.3%,
P ¼ .04; Table 4) and was 11% among patients with
invasive IE versus 4.4% among those with noninvasive
disease (P<.0001). Renal failure was also more common
after surgery for PVE and for invasive disease. Postopera-
tive atrial fibrillation was less common after surgery for
PVE. The use of an intra-aortic balloon pump was more
common after surgery for aortic valve IE (P ¼ .005).
Postoperative sepsis occurred in 10% of patients with
mitral IE and 5.1% of those with aortic valve IE (P ¼ .02).TABLE 3. Microbiologic etiology of infective endocarditis
Microorganism*
Noninvasive (n ¼ 323)
Overall NVE (n ¼ 240) PVE (n ¼ 83) P value
Staphylococcus aureus 71 (22) 58 (24) 13 (16) .11
Coagulase-negative
Staphylococcus
40 (12) 25 (10) 15 (18) .07
Enterococcus 42 (13) 33 (14) 9 (11) .5
Streptococcus viridans 70 (22) 62 (26) 8 (10) .002
Gram-positive cocciy 21 (6.5) 19 (7.9) 2 (2.4) .08
Fungal 8 (2.5) 1 (0.42) 7 (8.4) <.0001
Polymicrobial 12 (3.7) 9 (3.8) 3 (3.6) >.9
Other 23 (7.1) 11 (4.6) 12 (15) .003
Not identified 36 (11) 22 (9.2) 14 (17) .05
Data presented as n (%). NVE, Native valve endocarditis; PVE, prosthetic valve endocard
984 The Journal of Thoracic and Cardiovascular SurgSurvival
Overall unadjusted survival at 30 days, 6 months, and 1,
3, 5, and 7 years for these endocarditis patients was 92%,
84%, 81%, 72%, 66%, and 60%, respectively. The hazard
function resolved to 2 phases, with an early phase lasting
about 6 months and accounting for about one half of the
245 deaths, and a late declining phase thereafter. Survival
was higher for those with isolated aortic valve IE than for
the mitral and combined groups (73% at 5 years vs 60%
and 51%, respectively; P<.0001; Figure E2, A).
PVE versus NVE. Survival was similar after surgery for
PVE or NVE (67% vs 64% at 5 years; P[log-rank] ¼ .6;
Figure E2, B) and when stratified by valve (P ¼ .8 after
isolated aortic valve IE surgery, P ¼ .3 after isolated mitral
valve IE surgery, and P ¼ .4 after combined aortic and
mitral valve IE surgery; Figure 1).
Disease invasiveness. Survival was worse after surgery for
invasive IE than after surgery for noninvasive disease, with
a 5-year survival of 62% versus 70%, respectively
(Figure E2, C). However, when stratified by affected valve
position, invasive mitral IE and invasive double valve IEInvasive (n ¼ 452) P value
(invasive vs
noninvasive)Overall NVE (n ¼ 173) PVE (n ¼ 279) P value
122 (27) 59 (34) 63 (23) .007 .11
99 (22) 24 (14) 75 (27) .0012 .0007
51 (11) 21 (12) 30 (11) .6 .5
50 (11) 26 (15) 24 (8.6) .03 <.0001
25 (5.5) 17 (9.8) 8 (2.9) .002 .6
11 (2.5) 2 (1.2) 9 (3.2) .17 >.9
12 (2.7) 6 (3.5) 6 (2.2) .4 .4
46 (10) 11 (6.4) 35 (13) .03 .14
36 (8.0) 7 (4.1) 29 (10) .02 .13
itis. *Final diagnosis. yNot identified further.
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TABLE 4. In-hospital complications after surgery for left-sided endocarditis
Complication NVE (n ¼ 413) PVE (n ¼ 362) P value Noninvasive (n ¼ 323) Invasive (n ¼ 452) P value
In-hospital death 26 (6.3) 37 (10) .04 14 (4.4) 49 (11) .001
Bleeding 30 (7.2) 24 (6.7) .8 19 (5.9) 35 (7.7) .3
Stroke 16 (3.9) 14 (3.9) .9 12 (3.7) 18 (4) .9
New renal failure requiring dialysis 27 (6.5) 34 (9.5) .13 17 (5.3) 44 (9.7) .02
Renal failure 55 (13) 80 (22) .001 41 (13) 94 (21) .004
Prolonged ventilation (>24 h) 145 (35) 151 (42) .04 96 (30) 200 (44) <.0001
Sepsis 36 (8.7) 34 (9.5) .13 21 (6.5) 49 (11) .04
Atrial fibrillation 110 (29) 50 (16) <.0001 71 (24) 89 (22) .4
Use of IABP 12 (2.9) 18 (5.0) .13 7 (2.2) 23 (5.1) .04
Length of stay*
ICU (h) 25, 74, 335 27, 102, 327 .02 25, 67, 282 28, 114, 357 <.0001
Postoperative (d) 6.2, 12, 22 6.8, 12, 26 .2 6.1, 10, 23 7.0, 13, 24 .002
Hospital (d) 10, 19, 36 11, 19, 36 .2 10, 18, 34 11, 19, 37 .2
Data presented as n (%), unless otherwise noted. NVE, Native valve endocarditis; PVE, prosthetic valve endocarditis; IABP, intra-aortic balloon pumping; ICU, intensive care
unit. *Data presented as 15th, 50th, 85th percentiles.
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Dwere associated with worse survival, but invasive and
noninvasive aortic valve IE as well as noninvasive mitral
valve IE and noninvasive double valve disease were all
associated with similar and better survival than were
invasive mitral and invasive double valve IE (Figure 2).
Risk-adjusted mortality. Invasive IE involving the mitral
valve was associated with much worse survival than
invasive aortic valve disease (46% vs 74% at 5 years,
respectively; P< .0001; Figure E3, A). Although the risk
estimates stayed the same, this was not the case for the
propensity-matched patients (55% vs 73% at 5 years;
P ¼ .4, Figure E3, B). This resulted from differences in
the risk factors for early mortality, such as elevated bilirubin
and blood urea nitrogen, peripheral arterial disease, and
older age, as well as differences in risk factors for lateFIGURE 1. Survival after surgery for native or prosthetic valve left-sided
valve infective endocarditis (IE). Each symbol represents a death,
and vertical bars represent the 68% confidence limits, equivalent to
1 standard error. Solid green lines indicate native valve endocarditis;
dashed orange lines, prosthetic valve endocarditis; filled circles, aortic
valve IE alone; open circles, mitral valve IE alone; and triangles, aortic
and mitral valve IE.
The Journal of Thoracic and Casurvival, including older age and chronic obstructive
pulmonary disease (Table E2). Thus, unmatched patients
with invasive mitral valve disease had particularly poor
survival (Figure 3).DISCUSSION
As a paradoxical effect of advances in medical and
surgical therapy, the incidence of IE has increased during
the past 30 years.15-19 People live longer, undergo
procedures with the potential for bacteremia, and an
increasing number undergo heart surgery or receive
prosthetic valves, pacemakers, and defibrillators, all
factors associated with an increased risk of IE.
To our knowledge, our report represents the first
endocarditis study in which pathologic type has been
systematically coded and staged, as described in an earlierFIGURE 2. Survival after surgery for invasive versus noninvasive
left-sided infective endocarditis according to valve position. Solid blue
lines indicate noninvasive infective endocarditis; and dashed red lines,
invasive infective endocarditis. Each symbol represents a death, and
vertical bars represent the 68% confidence limits, equivalent to
1 standard error.
rdiovascular Surgery c Volume 148, Number 3 985
FIGURE 3. Survival after surgery for invasive infective endocarditis for
propensity-matched and unmatched isolated aortic and mitral valve cases.
Each symbol represents a death, and vertical bars represent the 68%
confidence limits, equivalent to 1 standard error.
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Dpublication,8 with outcomes analyzed by disease
invasiveness and stage. The present study also reports a
contemporary surgical experience with IE at a surgically
aggressive tertiary center operating on>100 patients with
IE annually.
Traditionally, the general disease factors associated with
worse outcomes after surgery for left-sided IE have been
PVE, the presence of an abscess, and an aggressive
organism (S aureus). In the present study, we focused,
not only on these factors, but also on a direct comparison of
aortic and mitral IE. This revealed several new observations
of differences between them. There were almost twice as
many aortic cases as mitral cases, the aortic cases had a
much higher percentage of PVE, and the aortic disease was
correspondingly more invasive. The characteristics of the
patient population affected by mitral valve IE were very
different from those of patients with aortic valve IE, with the
mitral patients at greater risk (Figure E1, B). Although
overall mortality was 8%, better than we have reported
previously, it was still higher than that for any other surgical
valve disease.15-18 Both mortality and survival were worse
for mitral IE than for aortic IE and even worse for combined
aortic and mitral IE. The characteristics and behavior of
concomitant mitral and aortic valve IE were more like those
of mitral valve disease. Similar outcomes for mitral IE have
been reported previously.6,20
In our present study, PVE, although associated with
greater hospital mortality, was not associated with worse
survival than NVE in any group, although the PVE patients
were older and had more comorbidities. This is in contrast
to previous reports. For example, David and colleagues4
reported much worse long-term survival for patients with
PVE than for those with NVE. Leontyev and colleagues21
reported hospital mortality of 24% and 5-year survival of
37% in 152 PVE patients in a recent series. Worse
outcomes in PVE patients have been reported by several
others.22-28986 The Journal of Thoracic and Cardiovascular SurgIn contrast, in our study, the patients with invasive disease
had distinctly worse overall outcome, mortality, and
survival than those with noninvasive disease. However,
when analyzed by affected valve, this was true only
for invasive mitral valve IE. Although the statistical
significance disappeared after propensity matching, the
risk estimate remained the same. This is in agreement
with our perception that we have learned to master invasive
aortic IE but not invasive mitral IE. We debride the aortic
root extensively without fear because we trust that
reconstruction with an allograft will be easy and straight-
forward and produce excellent results. In contrast, mitral
valve IE is invasive to the atrioventricular groove, and
radical debridement, sterilization, and drainage of the
infected area are much more difficult. One concern is that
debridement is less controlled and suboptimal when
invasion into the atrioventricular groove is deep. In
addition, no replacement alternative is available for the
mitral valve that is equally simple to implant and as good
as the allograft is for the aortic valve; allograft mitral valve
replacement is not simple and is still experimental.29
Fortunately, a lower percentage of mitral valve IE is
invasive, and when invasive, few cases are deep and
extensive. In the published data, it is also well recognized
that IE with an annular or a periannular abscess is associated
with a worse prognosis, and operative mortalities as high as
31% have been reported. Differences among studies are
related to multiple factors, with the experience of the
surgical team an important one.1-6,22,30,31 However, these
studies combine aortic and mitral IE and do not separate
them. Also, in the published studies, it is difficult to
distinguish between invasive disease and PVE. For 135
patients with a paravalvular abscess treated surgically,
David and colleagues5 reported a mortality stratified
by the involved valve of 10.9%, 11.1%, and 30%,
respectively, for aortic, mitral, and combined aortic and
mitral endocarditis and by NVE versus PVE of 11.6%
and 19.7%, respectively.
Although the role of surgery in active IE has expanded,
the indications and timing of surgery are still debated.32-36
With increasing experience, surgical mortality for active
IE has decreased considerably,1 and surgeons have become
increasingly aggressive. We have all learned and accepted
the basic principles for how to manage such disease
operatively: Radical debridement of all infected tissues,
generous irrigation, use of allografts for aortic root
replacement when the aortic annulus is involved, use of
autologous pericardium when additional tissue is
needed, and avoidance of foreign material, prosthetic
grafts, and glue.1-3 The surgical results will depend on
many variables, including patient characteristics, timing
of surgery,32-36 whether an emergency procedure is
required,30,37 virulence of the organism,1,36,38 whether the
affected valve is native or prosthetic, and whether theery c September 2014
Hussain et al Acquired Cardiovascular Disease
A
C
Dinfection has extended into the valve annulus and
surrounding tissues, causing abscesses, fistulas, and
pseudoaneurysms with an increased risk of adverse
outcomes, including death. Although some organisms,
such as S aureus, are more aggressive and invasive than
others, most will eventually be invasive and destructive,
given enough time. That the pathologic stage is more
important than whether it is NVE or PVE suggests that
we should operate earlier to avoid allowing the infection
to become more invasive.
Strengths and Limitations
The present study was a contemporary, but retrospective,
study from a busy tertiary referral center with long-standing
interest in the surgical treatment of endocarditis. Coding of
the pathologic entity was based on all available information
and was done by a single surgeon, not the operating surgeon
in most cases. Survival bias has been brought up as a factor
unfairly favoring surgery39; however, we can operate only
on patients who are still alive and operable when we first
see them.
CONCLUSIONS
Hospital mortality for surgically treated left-sided IE has
decreased, and the added risk of PVE has been neutralized.
We attribute this to our aggressive team approach and
treatment strategies, including early surgery. However, the
outcomes are still worse for mitral valve IE. The residual
obstacles are related to the patient, the inherent mitral valve
anatomy in patients with invasive disease, and the lack of an
alternative mitral valve prosthesis optimal for IE.
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APPENDIX E1. VARIABLES CONSIDERED IN
MULTIVARIABLE ANALYSES
Demographic Data
Age (years), sex, race (black, white, other), height (cm),
weight (kg), body surface area (m2), bodymass index (kg/m2)
Presentation
New York Heart Association functional class (I-IV),
emergency or salvage operation, complete heart block,
previous stroke, previous myocardial infarction
Cardiac Comorbidity
Preoperative atrial fibrillation, systolic blood pressure
(mm Hg), diastolic blood pressure (mm Hg), number of
previous cardiac operations, heart failure
Noncardiac Comorbidity
Pharmacologically treated diabetes (insulin and
noninsulin dependent), hypertension, peripheral arterial
disease, history of smoking, chronic obstructive pulmonary
disease, renal failure requiring dialysis, blood urea nitrogen
(mg/dL), creatinine (mg/dL), bilirubin (mg/dL), cholesterol
(mg/dL) (total, high-density lipoprotein, low-density
lipoprotein), triglycerides (mg/dL), hematocrit (%)
Preoperative Echocardiographic Data
Aortic valve regurgitation grade, mitral valve regurgita-
tion grade, tricuspid valve regurgitation grade, aortic valve
stenosis, mitral valve stenosis, left ventricular (LV) ejection
fraction (%), LV internal diastolic diameter (cm), LV
internal systolic diameter (cm), LV end-diastolic volume
(mL), LVend-systolic volume (mL), LV mass (g), left atrial
diameter (cm), left atrial volume (mL)
Procedural
Type of aortic or mitral valve surgery (repair;
replacement with mechanical valve, xenograft, or allograft;
native or prosthetic), concomitant tricuspid valve
surgery, coronary artery bypass grafting, use of internal
thoracic artery, incision (full sternotomy or less invasive),
cardiopulmonary bypass time (min), aortic clamp time
(min), surgeon
Endocarditis Details
Prosthetic or native valve, invasive disease, micro-
organism pathology, Duke criteria
Experience
Date of operation (days from January 1, 2002, to surgery)
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FIGURE E1. Results of propensity matching for various isolated invasive mitral valve infective endocarditis and isolated invasive aortic valve disease.
A, Mirrored histogram of propensity score distribution.Darkened bars represent matched patients. B, Covariable balance before and after matching. Values
on the horizontal axis represent the percentage standardized difference* between mitral valve and aortic valve IE groups. C, Standardized differences*
between matched and unmatched cases. PVE, prosthetic valve endocarditis; CoNS, coagulase-negative staphylococci; COPD, chronic obstructive
pulmonary disease; LVEF, left ventricular ejection fraction; Afib, atrial fibrillation; NYHA, New York Heart Association; GP, gram-positive; BUN, blood
urea nitrogen; Preop, preoperative; DM, diabetes mellitus; LA, left atrial; AV, aortic valve; MV, mitral valve. *Austin PC, Mamdani MM. A comparison
of propensity score methods; a case study estimating the effectiveness of post-MI statin use. Stat Med. 2006;25:2084-106.
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FIGURE E2. Survival after surgery for left-sided infective endocarditis (IE). Each symbol represents a death, and vertical bars represent the 68%
confidence limits, equivalent to 1 standard error. A, Stratified by involved valve. Filled circles indicate aortic valve IE alone; open circles, mitral valve
IE alone; and triangles, aortic and mitral valve IE. B, Stratified by native (solid green line and open circles) versus prosthetic (dashed orange line and
filled circles) valve endocarditis. C, Invasive (dashed red line and filled circles) versus noninvasive (solid blue line and open circles) disease.
FIGURE E3. Survival after surgery for invasive aortic valve infective endocarditis (IE) versus mitral disease. Each symbol represents a death, and
vertical bars represent the 68% confidence limits, equivalent to 1 standard error. Solid lines indicate parametric estimates enclosed within a 68%
confidence band.Orange solid line and filled circles indicate aortic valve IE; and purple solid line and open circles, mitral valve IE. A, Unadjusted survival.
B, Propensity-matched patients.
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TABLE E1. Preoperative patient characteristics associated with
invasive isolated mitral valve infective endocarditis (vs invasive
isolated aortic disease)
Factor Coefficient ± SE P value Reliability (%)*
NVE 2.2  0.34 <.0001 95
Previous stroke 0.78  0.33 .02 30
Preoperative dialysis 0.88  0.39 .02 30
Larger LA volume 0.044  0.0078 <.0001 84
Female sex 1.5  0.33 <.0001 69
Intercept 5.4  0.59 <.0001 —
C-statistic ¼ 0.85. SE, Standard error; NVE, native valve endocarditis; LA, left atrial.
*Percentage of times factor appeared in 1000 bootstrap models.
TABLE E2. Incremental risk factors for death after surgery for left-
sided infective endocarditis
Factor Coefficient ± SE P value
Early phase
Older age* 0.27  0.14 .05
Higher bilirubiny 0.74  0.15 <.0001
Higher blood urea nitrogeny 0.91  0.17 <.0001
Peripheral arterial disease 1.2  0.24 <.0001
Concomitant CABG 0.72  0.24 .003
MVonly groupz 0.031  0.38 .9
Combined AV and MV groupz 0.52  0.29 .08
Invasive disease in AV IE 0.040  0.34 .9
Invasive disease in MV IE 0.30  0.30 .3
PVE 0.33  0.26 .2
Late phase
Older age* 0.40  0.108 .0002
Lower hematocrity 1.6  0.44 .003
COPD 0.59  0.21 .005
Preoperative dialysis 1.9  0.21 <.0001
Left atrial diameter>6 cm 1.14  0.39 .004
Lower cholesterolx 0.073  0.024 .003
MV affectedjj 0.65  0.23 .005
Invasive disease in aortic IE 0.081  0.21 .7
Invasive disease in mitral IE 0.18  0.26 .5
SE, Standard error; CABG, coronary artery bypass grafting; MV, mitral valve;
AV, aortic valve; IE, infective endocarditis; PVE, prosthetic valve endocarditis;
COPD, chronic obstructive pulmonary disease. *Exp(age/50), exponential
transformation. yLogarithmic transformation. zCompared with AV group.
x(200/cholesterol)2, inverse squared transformation. jjMV group and combined
AV and MV group compared with AV group.
TABLE E3. Clinical and management characteristics of patients









Age (y) 58  15 57  14 55  15
Female sex 92 (23) 102 (43) 38 (27)
Presentation
NYHA functional class III-IV 108 (27) 76 (32) 48 (34)
Emergency or salvage 18 (4.6) 15 (6.3) 9 (6.4)
Previous stroke 120 (30) 100 (42) 47 (33)
Previous MI 105 (27) 55 (23) 29 (21)
Complete heart block or pacer 35 (9.0) 12 (5.2) 16 (12)
Acute or chronic renal disease
requiring DM
43 (11) 42 (18) 22 (16)
Preoperative length of stay (d)* 1.9, 5.4, 11 1.8, 6.6, 13 1.9, 5.9, 13
Cardiac morbidity
Previous cardiac operation
None 147 (37) 134 (56) 68 (48)
1 176 (45) 70 (30) 49 (35)
2 60 (15) 23 (9.7) 20 (14)
3 12 (3.0) 10 (4.2) 4 (2.8)
AV
Stenosis 32 (8.1) 9 (3.8) 14 (9.9)
Regurgitation grade 3þ/4þ 214 (56) 2 (0.96) 68 (50)
MV
Stenosis 1 (0.25) 24 (10) 7 (5.0)
Regurgitation grade 3þ/4þ 41 (11) 125 (55) 56 (42)
Noncardiac comorbidity
Hypertension 269 (68) 158 (67) 82 (58)
Pharmacologically treated DM 82 (21) 65 (28) 25 (18)
COPD 66 (17) 33 (14) 25 (18)
Peripheral arterial disease 46 (12) 32 (14) 14 (9.9)
Operative management
AV repair 9 (2.3) 4 (1.7) 7 (4.9)
AV replacement
Mechanical 14 (3.5) 0 (0) 11 (7/8)
Xenograft 78 (20) 10 (4.2) 51 (36)
Allograft 287 (73) 2 (0.84) 68 (48)
MV repair 57 (14) 67 (28) 67 (47)
MV replacement
Mechanical 0 (0) 29 (12) 10 (7.0)
Xenograft 5 (1.3) 142 (60) 63 (44)
CPB time (min) 160  66 121  47 193  79
Aortic clamp time (min) 120  44 91  39 154  63
Data presented as mean  standard deviation or n (%), unless otherwise noted. AV,
Aortic valve;MV, mitral valve; NYHA, New York Heart Association;MI, myocardial
infarction; DM, diabetes mellitus; COPD, chronic obstructive pulmonary disease;
CPB, cardiopulmonary bypass. *Data presented as 15th, 50th, 85th percentiles.
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